An observational study in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Mantle-Cell, sponsored by Johnson & Johnson Private Limited. Completed at 8 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson — 3 open to participants now, 7 under way, 2 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Johnson & Johnson.
Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, this one is one of 3 that started in 2018, is one of 7 observational ones, and was the 15th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Romania
Ages 18+
Janssen Cilag S.A.S. · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 146 across 215 observational studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 134 across the 18 interventional studies, 180 across the 7 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Johnson & Johnson Private Limited, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Private Limited is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
1 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the effectiveness (overall response rate [ORR] and time to progression [TPP]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Study population include chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma (MCL) participants treated with ibrutinib per routine clinical care before 30 April 2018 in India and who have progressed on at least one prior line of therapy or CLL participants with deletion 17p (deletions in the short arm of chromosome 17).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
Drug: Ibrutinib
This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
Drug: Ibrutinib
No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
Also known as: IMBRUVICA
Overall Response Rate (ORR)
ORR is defined as achievement of complete response (CR) or partial response (PR) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 guidelines for Chronic Lymphocytic Leukemia (CLL) and Mantle-cell Lymphoma (MCL). CR is defined as resolution of enlarged lymph nodes, spleen and liver; normalization of blood counts (neutrophils, hemoglobin, platelets); no residual CLL/MCL detectable in the bone marrow. PR is defined as 50 percent (%) or more reduction in size of enlarged lymph nodes, liver or spleen; 50% or more improvement of blood counts; 50% or more reduction in the blood lymphocyte count.
Time frame: Up to 14 months
Time to Progression (TTP)
Time to progression will be reported for the observed participants receiving ibrutinib. TTP is defined as the period from study entry until objective disease progression (time from the date of randomization until disease progression or death due to progression, whichever occur first).
Time frame: Up to 14 months
Percentage of Participants with Complete Response (CR)
Percentage of participants with CR will be reported. CR is defined as resolution of enlarged lymph nodes, spleen and liver; normalization of blood counts (neutrophils, hemoglobin, platelets); no residual CLL/MCL detectable in the bone marrow.
Time frame: Up to 14 months
Percentage of Participants with Partial Response (PR)
Percentage of participants with PR will be reported. PR is defined as 50 percent (%) or more reduction in size of enlarged lymph nodes, liver or spleen; 50% or more improvement of blood counts; 50% or more reduction in the blood lymphocyte count.
Time frame: Up to 14 months
Percentage of Participants with Stable Disease (SD)
Percentage of participants with SD will be reported. Participants who have not achieved a CR or a PR, and who have not exhibited progressive disease will be considered to have stable disease.
Time frame: Up to 14 months
Percentage of Participants with Progressive Disease (PD)
Percentage of participants with PD will be reported. PD is defined as 50% or more increase in lymph nodes or the appearance of new enlarged lymph nodes; 50% or more increase in the size of the spleen or liver; 50% or more increase in blood lymphocyte count.
Time frame: Up to 14 months
Median time to Response with Ibrutinib
Median time to response with ibrutinib in CLL and MCL participants will be reported. Time to response is defined as the time from start of ibrutinib therapy until objective response (CR or PR assessed by the investigator, based on physical examinations, CT scans, laboratory results, and bone marrow examinations, according to the modified 2008 IWCLL response criteria).
Time frame: Up to 14 months
Change from Baseline in Hemoglobin Levels
Change from baseline in blood hemoglobin level will be reported.
Time frame: Baseline up to 14 months
Change from Baseline in Platelet Counts
Change from baseline in blood platelet counts will be reported.
Time frame: Baseline up to 14 months
Number of Participants with Response to Ibrutinib by Prior Lines of Therapy
Number of participants, who progresses on at least one prior line of therapy, with response to ibrutinib will be reported.
Time frame: Up to 14 months
Number of Participants with Hematological and Non-hematological Adverse Drug Reactions (ADR)
Number of participants with hematological and non-hematological ADR will be reported. An adverse drug reaction (ADR) is defined as a response to a medicinal (investigational or non-investigational) product that is noxious and unintended. The phrase "response to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is possible, probable or very likely.
Time frame: Up to 14 months
Ran from Apr 2018 to primary completion in May 2019, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →
Johnson & Johnson Private Limited →